<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02150343</url>
  </required_header>
  <id_info>
    <org_study_id>TH005</org_study_id>
    <nct_id>NCT02150343</nct_id>
  </id_info>
  <brief_title>Phase II HDM-SPIRE Safety and Efficacy Study</brief_title>
  <official_title>A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects With a History of House Dust Mite-Induced Rhinoconjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Circassia Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quintiles, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Circassia Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the treatment effect of three treatment regimens of
      HDM-SPIRE vs placebo and to evaluates the treatment effect of HDM-SPIRE on symptoms, rescue
      medication usage, Quality of Life and Sleep Quality
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">April 13, 2017</completion_date>
  <primary_completion_date type="Actual">April 13, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined Score of Symptoms and Allergy Medication</measure>
    <time_frame>Weeks 50 to 52 after randomisation</time_frame>
    <description>The primary endpoint was mean Combined Score (CS) over a 3 week period (50-52 weeks after randomisation) in the HDM-SPIRE treatment groups compared with the mean CS in the placebo group. A higher score indicated more severe symptoms or greater use of allergy rescue medication and thus a low score indicated a better outcome.
CS = Total Rhinoconjunctivitis Symptom Score (TRSS) + Rescue Medication Score (RMS). Eight symptoms are defined in the TRSS, 4 nasal symptoms: runny nose, sneezing, blocked nose and itchy nose and 4 non-nasal symptoms: itchy eyes; watery eyes; red eyes, and sore eyes. Each symptom was rated in severity on a score of 0-3 (0=absent, 3=severe); TRSS was divided by the number of symptoms (8) to provide an average score per symptom of 0-3.
The RMS score ranged from 0 (no allergy rescue medication use per day) to 3 (at least one dose of systemic corticosteroid per day). The RMS score was not additive, and therefore the maximum RMS was 3 and the maximum CS was 6.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean RQLQ Score in HDM-SPIRE Treatment Groups Compared With Placebo</measure>
    <time_frame>Weeks 50 to 52 after randomisation</time_frame>
    <description>The RQLQ (Rhinoconjunctivitis Quality of Life Questionnaire) was completed by subjects at the end of the study (50-52 weeks after randomisation).
RQLQ is a validated method of assessing quality of life and has 28 questions in seven domains (activity limitation, sleep problems, nasal symptoms, eye symptoms, non-nasal/eye symptoms, practical problems and emotional function). Subjects recalled how their rhinoconjunctivitis had been during the last week and responded to each question on a seven-point scale (0 = no impairment, 6 = maximum impairment). Questions were equally weighted, and the RQLQ score was the mean of the 28 questions and could range from zero to six.
A higher score indicated greater impact on quality of life and thus a low score indicated a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Assessment of Change in Rhinoconjunctivitis Symptoms Measured by Rating Overall Symptoms at the End of the Study Relative to Baseline</measure>
    <time_frame>Weeks 50 to 52 after randomisation</time_frame>
    <description>A Global Impression of Change in Rhinoconjunctivitis Symptoms assessment was completed by subjects at the final follow-up visit. Subjects rated their overall allergy symptoms at the end of the study relative to baseline on a seven-point scale as follows:0. very much better; 1. moderately better; 2. a little better; 3. unchanged; 4. a little worse; 5. moderately worse; 6. very much worse.
For reporting the individual categories were grouped as follows: moderately or very much better; any improvement; no change and any worsening. Subjects could therefore be reported in more than group and the total number reported does not match the overall number of participants analysed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean TRSS in HDM-SPIRE Treatment Groups Compared With Placebo</measure>
    <time_frame>Weeks 50 to 52 after randomisation</time_frame>
    <description>Mean Total Rhinoconjunctivitis Symptom Score (TRSS) in HDM-SPIRE treatment groups compared with placebo.
Eight symptoms are defined in the TRSS, 4 nasal symptoms: runny nose, sneezing; blocked nose, and itchy nose and 4 non-nasal symptoms: itchy eyes; watery eyes; red eyes, and sore eyes. Each symptom was rated in severity on a score of 0-3 (0. absent; 1. mild, barely noticeable; 2. moderate, annoying/troublesome; 3. severe, very annoying/very troublesome), therefore TRSS could range from 0 to 24. Higher TRSS reflected more severe symptom scores. Symptoms were scored daily for a period of approximately 3 weeks, 50-52 weeks after randomisation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Non-nasal Score in HDM-SPIRE Treatment Group Compared With Placebo</measure>
    <time_frame>Weeks 50 to 52 after randomisation</time_frame>
    <description>Mean daily Total Non-nasal Symptom Score (TNNSS) in HDM-SPIRE treatment groups compared to placebo. TNNSS was the sum of all the non-nasal symptom scores (itchy eyes; watery eyes; red eyes; sore eyes) and could range from 0 to 12. Higher TNNSS reflected more severe symptoms.
Subjects rated the severity of each symptom over the last 24 hours as follows: 0. absent; 1. mild, barely noticeable; 2. moderate, annoying/troublesome; 3. severe, very annoying/very troublesome. Symptoms were scored daily for a period of approximately 3 weeks, 50-52 weeks after randomisation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Nasal Score in HDM-SPIRE Treatment Group Compared With Placebo</measure>
    <time_frame>Weeks 50 to 52 after randomisation</time_frame>
    <description>TNSS (Total nasal symptom score) was the sum of all the nasal symptom scores (runny nose; sneezing; blocked nose; itchy nose) and could range from 0 to 12. Higher TNSS reflected more severe symptoms.
Subjects rated the severity of each symptom over the last 24 hours as follows: 0. absent; 1. mild, barely noticeable; 2. moderate, annoying/troublesome; 3. severe, very annoying/very troublesome. Symptoms were scored daily for a period of approximately 3 weeks, 50-52 weeks after randomisation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean RMS in HDM-SPIRE Treatment Group Compared With Placebo</measure>
    <time_frame>Weeks 50 to 52 after randomisation</time_frame>
    <description>Mean RMS (Rescue medication score) in HDM-SPIRE treatment groups compared with placebo groups.
The use of rhinoconjunctivitis rescue medications was recorded by the subject on a daily basis just before bedtime for approximately 21 days, 50-52 weeks after randomisation and was scored based on a previously published system as follows: 0 = no allergy rescue medication used per day; 0.5 = at least one dose of antihistamine eye drops used per day; 1 = at least one dose of oral antihistamine used per day; 2 = at least one dose of intranasal corticosteroid used per day; 3 = at least one dose of systemic corticosteroid used per day. The score was according to the highest level of rescue medication used and was not additive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days With no Rescue Medication Use in HDM-SPIRE Treatment Group Compared With Placebo</measure>
    <time_frame>Weeks 50 to 52 after randomisation</time_frame>
    <description>The number of well days, i.e., days with no moderately or severely annoying symptoms and with no rescue medication used was calculated for all subjects over a period of approximately 21 days, 50-52 weeks after randomisation.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">715</enrollment>
  <condition>Rhinoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>HMD-SPIRE Treatment 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 x 12 nmol HDM-SPIRE followed by 4 x placebo 4 weeks apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HDM-SPIRE Treatment 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 x 12 nmol HDM-SPIRE 4 weeks apart followed by a second course of 4 x 12 nmol HDM-SPIRE 4 weeks apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HDM-SPIRE Treatment 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 x 20 nmol HDM-SPIRE followed by 4 x placebo 4 weeks apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>8 x placebo 4 weeks apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HDM-SPIRE</intervention_name>
    <description>1 dose every 4 weeks</description>
    <arm_group_label>HDM-SPIRE Treatment 2</arm_group_label>
    <arm_group_label>HDM-SPIRE Treatment 3</arm_group_label>
    <arm_group_label>HMD-SPIRE Treatment 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 dose every 4 weeks</description>
    <arm_group_label>HDM-SPIRE Treatment 3</arm_group_label>
    <arm_group_label>HMD-SPIRE Treatment 1</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, aged 18-65 years.

          -  Moderate to severe rhinoconjunctivitis on exposure to HDM for at least 1 years.

          -  Mean TRSS ≥10

          -  Positive skin prick test to Der p and Der f.

          -  Dep p and Der f specific IgE ≥0.7 kU/L

        Exclusion Criteria:

          -  Diagnosis of asthma requiring Global Initiative for Asthma (GINA) Step 3
             (www.ginasthma.org)or higher treatment

          -  FEV1 &lt;80% of predicted.

          -  Clinically significant confounding symptoms of allergy to seasonal allergens during
             the final evaluation period.

          -  Significant symptoms of another clinically relevant illness that is likely to affect
             scoring of rhinoconjunctivitis symptoms.

          -  Clinically relevant abnormalities detected on physical examination.

          -  History of severe drug allergy, severe angioedema or anaphylactic reaction to food.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Napa</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rolling Hills Estates</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shiloh</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gaithersburg</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ocean City</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Verona</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Blue Bell</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kerrville</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Burlington</city>
        <state>Vermont</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Henrico</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellingham</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenfield</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Niagara</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Romuald</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trois Rivieres</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reims</city>
        <state>Marne</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gironde</city>
        <state>Pessac</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bas Rhin</city>
        <state>Strasbourg</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Meurthe-et-Moselle</city>
        <state>Vandoeuvre Les Nancy</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <state>Baden Wuerttemberg</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <state>Nordrhein Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goch</city>
        <state>Nordrhein Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <state>Saxony</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ancona</city>
        <state>Torrette Di Ancona</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Almere</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beek</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durban</city>
        <state>KwaZulu-Natal</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ottawa</city>
        <state>KwaZulu-Natal</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Umkomaas</city>
        <state>KwaZulu-Natal</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Girona</city>
        <state>Catalonia</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Sebastian</city>
        <state>Guipuzcoa</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pamplona</city>
        <state>Navarre</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bilbao</city>
        <state>Vizcaya</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 27, 2014</study_first_submitted>
  <study_first_submitted_qc>May 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2014</study_first_posted>
  <results_first_submitted>March 29, 2018</results_first_submitted>
  <results_first_submitted_qc>May 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 15, 2018</results_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cat allergy</keyword>
  <keyword>Rhinoconjunctivitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 1, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT02150343/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 24, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT02150343/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>715 participants were randomised on to the study through the IRT. However, one participant was inadvertently randomised before eligibility had been confirmed by the PI, and was withdrawn due to a finding of inspiration/expiration wheeze before receiving any study medication. Therefore results refer to 714 participants throughout.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>HDM-SPIRE 12 Nmol (4 Administrations)</title>
          <description>12 nmol given at 4 weekly intervals (4 administrations)</description>
        </group>
        <group group_id="P2">
          <title>HDM-SPIRE 20 Nmol</title>
          <description>20 nmol given at 4 weekly intervals (4 administrations)</description>
        </group>
        <group group_id="P3">
          <title>HDM-SPIRE 12 Nmol (8 Administrations)</title>
          <description>20 nmol given at 4 weekly intervals (8 administrations)</description>
        </group>
        <group group_id="P4">
          <title>HDM-SPIRE Placebo</title>
          <description>8 administrations at 4 weekly intervals</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="180"/>
                <participants group_id="P2" count="178"/>
                <participants group_id="P3" count="178"/>
                <participants group_id="P4" count="178"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="159"/>
                <participants group_id="P2" count="158"/>
                <participants group_id="P3" count="166"/>
                <participants group_id="P4" count="168"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HDM-SPIRE 12 Nmol (4 Administrations)</title>
          <description>12 nmol given at 4 weekly intervals (4 administrations)</description>
        </group>
        <group group_id="B2">
          <title>HDM-SPIRE 20 Nmol</title>
          <description>20 nmol given at 4 weekly intervals (4 administrations)</description>
        </group>
        <group group_id="B3">
          <title>HDM-SPIRE 12 Nmol (8 Administrations)</title>
          <description>20 nmol given at 4 weekly intervals (8 administrations)</description>
        </group>
        <group group_id="B4">
          <title>HDM-SPIRE Placebo</title>
          <description>8 administrations at 4 weekly intervals</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="180"/>
            <count group_id="B2" value="178"/>
            <count group_id="B3" value="178"/>
            <count group_id="B4" value="178"/>
            <count group_id="B5" value="714"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.7" spread="11.53"/>
                    <measurement group_id="B2" value="38.3" spread="12.40"/>
                    <measurement group_id="B3" value="35.5" spread="11.61"/>
                    <measurement group_id="B4" value="36.8" spread="12.84"/>
                    <measurement group_id="B5" value="36.8" spread="12.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="120"/>
                    <measurement group_id="B4" value="117"/>
                    <measurement group_id="B5" value="453"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="61"/>
                    <measurement group_id="B5" value="261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="144"/>
                    <measurement group_id="B4" value="136"/>
                    <measurement group_id="B5" value="555"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Combined Score of Symptoms and Allergy Medication</title>
        <description>The primary endpoint was mean Combined Score (CS) over a 3 week period (50-52 weeks after randomisation) in the HDM-SPIRE treatment groups compared with the mean CS in the placebo group. A higher score indicated more severe symptoms or greater use of allergy rescue medication and thus a low score indicated a better outcome.
CS = Total Rhinoconjunctivitis Symptom Score (TRSS) + Rescue Medication Score (RMS). Eight symptoms are defined in the TRSS, 4 nasal symptoms: runny nose, sneezing, blocked nose and itchy nose and 4 non-nasal symptoms: itchy eyes; watery eyes; red eyes, and sore eyes. Each symptom was rated in severity on a score of 0-3 (0=absent, 3=severe); TRSS was divided by the number of symptoms (8) to provide an average score per symptom of 0-3.
The RMS score ranged from 0 (no allergy rescue medication use per day) to 3 (at least one dose of systemic corticosteroid per day). The RMS score was not additive, and therefore the maximum RMS was 3 and the maximum CS was 6.</description>
        <time_frame>Weeks 50 to 52 after randomisation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HDM-SPIRE 12 Nmol (4 Administrations)</title>
            <description>12 nmol given at 4 weekly intervals (4 administrations)</description>
          </group>
          <group group_id="O2">
            <title>HDM-SPIRE 20 Nmol</title>
            <description>20 nmol given at 4 weekly intervals (4 administrations)</description>
          </group>
          <group group_id="O3">
            <title>HDM-SPIRE 12 Nmol (8 Administrations)</title>
            <description>20 nmol given at 4 weekly intervals (8 administrations)</description>
          </group>
          <group group_id="O4">
            <title>HDM-SPIRE Placebo</title>
            <description>8 administrations at 4 weekly intervals</description>
          </group>
        </group_list>
        <measure>
          <title>Combined Score of Symptoms and Allergy Medication</title>
          <description>The primary endpoint was mean Combined Score (CS) over a 3 week period (50-52 weeks after randomisation) in the HDM-SPIRE treatment groups compared with the mean CS in the placebo group. A higher score indicated more severe symptoms or greater use of allergy rescue medication and thus a low score indicated a better outcome.
CS = Total Rhinoconjunctivitis Symptom Score (TRSS) + Rescue Medication Score (RMS). Eight symptoms are defined in the TRSS, 4 nasal symptoms: runny nose, sneezing, blocked nose and itchy nose and 4 non-nasal symptoms: itchy eyes; watery eyes; red eyes, and sore eyes. Each symptom was rated in severity on a score of 0-3 (0=absent, 3=severe); TRSS was divided by the number of symptoms (8) to provide an average score per symptom of 0-3.
The RMS score ranged from 0 (no allergy rescue medication use per day) to 3 (at least one dose of systemic corticosteroid per day). The RMS score was not additive, and therefore the maximum RMS was 3 and the maximum CS was 6.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="165"/>
                <count group_id="O4" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" spread="0.089"/>
                    <measurement group_id="O2" value="1.51" spread="0.089"/>
                    <measurement group_id="O3" value="1.40" spread="0.086"/>
                    <measurement group_id="O4" value="1.56" spread="0.087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean RQLQ Score in HDM-SPIRE Treatment Groups Compared With Placebo</title>
        <description>The RQLQ (Rhinoconjunctivitis Quality of Life Questionnaire) was completed by subjects at the end of the study (50-52 weeks after randomisation).
RQLQ is a validated method of assessing quality of life and has 28 questions in seven domains (activity limitation, sleep problems, nasal symptoms, eye symptoms, non-nasal/eye symptoms, practical problems and emotional function). Subjects recalled how their rhinoconjunctivitis had been during the last week and responded to each question on a seven-point scale (0 = no impairment, 6 = maximum impairment). Questions were equally weighted, and the RQLQ score was the mean of the 28 questions and could range from zero to six.
A higher score indicated greater impact on quality of life and thus a low score indicated a better outcome.</description>
        <time_frame>Weeks 50 to 52 after randomisation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HDM-SPIRE 12 Nmol (4 Administrations)</title>
            <description>12 nmol given at 4 weekly intervals (4 administrations)</description>
          </group>
          <group group_id="O2">
            <title>HDM-SPIRE 20 Nmol</title>
            <description>20 nmol given at 4 weekly intervals (4 administrations)</description>
          </group>
          <group group_id="O3">
            <title>HDM-SPIRE 12 Nmol (8 Administrations)</title>
            <description>20 nmol given at 4 weekly intervals (8 administrations)</description>
          </group>
          <group group_id="O4">
            <title>HDM-SPIRE Placebo</title>
            <description>8 administrations at 4 weekly intervals</description>
          </group>
        </group_list>
        <measure>
          <title>Mean RQLQ Score in HDM-SPIRE Treatment Groups Compared With Placebo</title>
          <description>The RQLQ (Rhinoconjunctivitis Quality of Life Questionnaire) was completed by subjects at the end of the study (50-52 weeks after randomisation).
RQLQ is a validated method of assessing quality of life and has 28 questions in seven domains (activity limitation, sleep problems, nasal symptoms, eye symptoms, non-nasal/eye symptoms, practical problems and emotional function). Subjects recalled how their rhinoconjunctivitis had been during the last week and responded to each question on a seven-point scale (0 = no impairment, 6 = maximum impairment). Questions were equally weighted, and the RQLQ score was the mean of the 28 questions and could range from zero to six.
A higher score indicated greater impact on quality of life and thus a low score indicated a better outcome.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="166"/>
                <count group_id="O4" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.02" spread="0.098"/>
                    <measurement group_id="O2" value="1.76" spread="0.098"/>
                    <measurement group_id="O3" value="1.72" spread="0.095"/>
                    <measurement group_id="O4" value="1.89" spread="0.095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Assessment of Change in Rhinoconjunctivitis Symptoms Measured by Rating Overall Symptoms at the End of the Study Relative to Baseline</title>
        <description>A Global Impression of Change in Rhinoconjunctivitis Symptoms assessment was completed by subjects at the final follow-up visit. Subjects rated their overall allergy symptoms at the end of the study relative to baseline on a seven-point scale as follows:0. very much better; 1. moderately better; 2. a little better; 3. unchanged; 4. a little worse; 5. moderately worse; 6. very much worse.
For reporting the individual categories were grouped as follows: moderately or very much better; any improvement; no change and any worsening. Subjects could therefore be reported in more than group and the total number reported does not match the overall number of participants analysed.</description>
        <time_frame>Weeks 50 to 52 after randomisation</time_frame>
        <population>The overall number of participants analysed represents the number of subjects that completed the assessment, not all subjects that completed the study (651) completed the Clinical Global Impression of Change (633).</population>
        <group_list>
          <group group_id="O1">
            <title>HDM-SPIRE 12 Nmol (4 Administrations)</title>
            <description>12 nmol given at 4 weekly intervals (4 administrations)</description>
          </group>
          <group group_id="O2">
            <title>HDM-SPIRE 20 Nmol</title>
            <description>20 nmol given at 4 weekly intervals (4 administrations)</description>
          </group>
          <group group_id="O3">
            <title>HDM-SPIRE 12 Nmol (8 Administrations)</title>
            <description>20 nmol given at 4 weekly intervals (8 administrations)</description>
          </group>
          <group group_id="O4">
            <title>HDM-SPIRE Placebo</title>
            <description>8 administrations at 4 weekly intervals</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Assessment of Change in Rhinoconjunctivitis Symptoms Measured by Rating Overall Symptoms at the End of the Study Relative to Baseline</title>
          <description>A Global Impression of Change in Rhinoconjunctivitis Symptoms assessment was completed by subjects at the final follow-up visit. Subjects rated their overall allergy symptoms at the end of the study relative to baseline on a seven-point scale as follows:0. very much better; 1. moderately better; 2. a little better; 3. unchanged; 4. a little worse; 5. moderately worse; 6. very much worse.
For reporting the individual categories were grouped as follows: moderately or very much better; any improvement; no change and any worsening. Subjects could therefore be reported in more than group and the total number reported does not match the overall number of participants analysed.</description>
          <population>The overall number of participants analysed represents the number of subjects that completed the assessment, not all subjects that completed the study (651) completed the Clinical Global Impression of Change (633).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="158"/>
                <count group_id="O4" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Moderately or very much better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="109"/>
                    <measurement group_id="O3" value="103"/>
                    <measurement group_id="O4" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="48"/>
                    <measurement group_id="O4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any worsening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean TRSS in HDM-SPIRE Treatment Groups Compared With Placebo</title>
        <description>Mean Total Rhinoconjunctivitis Symptom Score (TRSS) in HDM-SPIRE treatment groups compared with placebo.
Eight symptoms are defined in the TRSS, 4 nasal symptoms: runny nose, sneezing; blocked nose, and itchy nose and 4 non-nasal symptoms: itchy eyes; watery eyes; red eyes, and sore eyes. Each symptom was rated in severity on a score of 0-3 (0. absent; 1. mild, barely noticeable; 2. moderate, annoying/troublesome; 3. severe, very annoying/very troublesome), therefore TRSS could range from 0 to 24. Higher TRSS reflected more severe symptom scores. Symptoms were scored daily for a period of approximately 3 weeks, 50-52 weeks after randomisation.</description>
        <time_frame>Weeks 50 to 52 after randomisation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HDM-SPIRE 12 Nmol (4 Administrations)</title>
            <description>12 nmol given at 4 weekly intervals (4 administrations)</description>
          </group>
          <group group_id="O2">
            <title>HDM-SPIRE 20 Nmol</title>
            <description>20 nmol given at 4 weekly intervals (4 administrations)</description>
          </group>
          <group group_id="O3">
            <title>HDM-SPIRE 12 Nmol (8 Administrations)</title>
            <description>20 nmol given at 4 weekly intervals (8 administrations)</description>
          </group>
          <group group_id="O4">
            <title>HDM-SPIRE Placebo</title>
            <description>8 administrations at 4 weekly intervals</description>
          </group>
        </group_list>
        <measure>
          <title>Mean TRSS in HDM-SPIRE Treatment Groups Compared With Placebo</title>
          <description>Mean Total Rhinoconjunctivitis Symptom Score (TRSS) in HDM-SPIRE treatment groups compared with placebo.
Eight symptoms are defined in the TRSS, 4 nasal symptoms: runny nose, sneezing; blocked nose, and itchy nose and 4 non-nasal symptoms: itchy eyes; watery eyes; red eyes, and sore eyes. Each symptom was rated in severity on a score of 0-3 (0. absent; 1. mild, barely noticeable; 2. moderate, annoying/troublesome; 3. severe, very annoying/very troublesome), therefore TRSS could range from 0 to 24. Higher TRSS reflected more severe symptom scores. Symptoms were scored daily for a period of approximately 3 weeks, 50-52 weeks after randomisation.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="165"/>
                <count group_id="O4" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.96" spread="0.468"/>
                    <measurement group_id="O2" value="8.03" spread="0.467"/>
                    <measurement group_id="O3" value="7.97" spread="0.451"/>
                    <measurement group_id="O4" value="8.16" spread="0.455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Non-nasal Score in HDM-SPIRE Treatment Group Compared With Placebo</title>
        <description>Mean daily Total Non-nasal Symptom Score (TNNSS) in HDM-SPIRE treatment groups compared to placebo. TNNSS was the sum of all the non-nasal symptom scores (itchy eyes; watery eyes; red eyes; sore eyes) and could range from 0 to 12. Higher TNNSS reflected more severe symptoms.
Subjects rated the severity of each symptom over the last 24 hours as follows: 0. absent; 1. mild, barely noticeable; 2. moderate, annoying/troublesome; 3. severe, very annoying/very troublesome. Symptoms were scored daily for a period of approximately 3 weeks, 50-52 weeks after randomisation.</description>
        <time_frame>Weeks 50 to 52 after randomisation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HDM-SPIRE 12 Nmol (4 Administrations)</title>
            <description>12 nmol given at 4 weekly intervals (4 administrations)</description>
          </group>
          <group group_id="O2">
            <title>HDM-SPIRE 20 Nmol</title>
            <description>20 nmol given at 4 weekly intervals (4 administrations)</description>
          </group>
          <group group_id="O3">
            <title>HDM-SPIRE 12 Nmol (8 Administrations)</title>
            <description>20 nmol given at 4 weekly intervals (8 administrations)</description>
          </group>
          <group group_id="O4">
            <title>HDM-SPIRE Placebo</title>
            <description>8 administrations at 4 weekly intervals</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Non-nasal Score in HDM-SPIRE Treatment Group Compared With Placebo</title>
          <description>Mean daily Total Non-nasal Symptom Score (TNNSS) in HDM-SPIRE treatment groups compared to placebo. TNNSS was the sum of all the non-nasal symptom scores (itchy eyes; watery eyes; red eyes; sore eyes) and could range from 0 to 12. Higher TNNSS reflected more severe symptoms.
Subjects rated the severity of each symptom over the last 24 hours as follows: 0. absent; 1. mild, barely noticeable; 2. moderate, annoying/troublesome; 3. severe, very annoying/very troublesome. Symptoms were scored daily for a period of approximately 3 weeks, 50-52 weeks after randomisation.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="165"/>
                <count group_id="O4" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.99" spread="0.242"/>
                    <measurement group_id="O2" value="3.64" spread="0.242"/>
                    <measurement group_id="O3" value="3.53" spread="0.233"/>
                    <measurement group_id="O4" value="3.73" spread="0.235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Nasal Score in HDM-SPIRE Treatment Group Compared With Placebo</title>
        <description>TNSS (Total nasal symptom score) was the sum of all the nasal symptom scores (runny nose; sneezing; blocked nose; itchy nose) and could range from 0 to 12. Higher TNSS reflected more severe symptoms.
Subjects rated the severity of each symptom over the last 24 hours as follows: 0. absent; 1. mild, barely noticeable; 2. moderate, annoying/troublesome; 3. severe, very annoying/very troublesome. Symptoms were scored daily for a period of approximately 3 weeks, 50-52 weeks after randomisation.</description>
        <time_frame>Weeks 50 to 52 after randomisation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HDM-SPIRE 12 Nmol (4 Administrations)</title>
            <description>12 nmol given at 4 weekly intervals (4 administrations)</description>
          </group>
          <group group_id="O2">
            <title>HDM-SPIRE 20 Nmol</title>
            <description>20 nmol given at 4 weekly intervals (4 administrations)</description>
          </group>
          <group group_id="O3">
            <title>HDM-SPIRE 12 Nmol (8 Administrations)</title>
            <description>20 nmol given at 4 weekly intervals (8 administrations)</description>
          </group>
          <group group_id="O4">
            <title>HDM-SPIRE Placebo</title>
            <description>8 administrations at 4 weekly intervals</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Nasal Score in HDM-SPIRE Treatment Group Compared With Placebo</title>
          <description>TNSS (Total nasal symptom score) was the sum of all the nasal symptom scores (runny nose; sneezing; blocked nose; itchy nose) and could range from 0 to 12. Higher TNSS reflected more severe symptoms.
Subjects rated the severity of each symptom over the last 24 hours as follows: 0. absent; 1. mild, barely noticeable; 2. moderate, annoying/troublesome; 3. severe, very annoying/very troublesome. Symptoms were scored daily for a period of approximately 3 weeks, 50-52 weeks after randomisation.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="165"/>
                <count group_id="O4" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.99" spread="0.244"/>
                    <measurement group_id="O2" value="4.40" spread="0.243"/>
                    <measurement group_id="O3" value="4.45" spread="0.235"/>
                    <measurement group_id="O4" value="4.44" spread="0.237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean RMS in HDM-SPIRE Treatment Group Compared With Placebo</title>
        <description>Mean RMS (Rescue medication score) in HDM-SPIRE treatment groups compared with placebo groups.
The use of rhinoconjunctivitis rescue medications was recorded by the subject on a daily basis just before bedtime for approximately 21 days, 50-52 weeks after randomisation and was scored based on a previously published system as follows: 0 = no allergy rescue medication used per day; 0.5 = at least one dose of antihistamine eye drops used per day; 1 = at least one dose of oral antihistamine used per day; 2 = at least one dose of intranasal corticosteroid used per day; 3 = at least one dose of systemic corticosteroid used per day. The score was according to the highest level of rescue medication used and was not additive.</description>
        <time_frame>Weeks 50 to 52 after randomisation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HDM-SPIRE 12 Nmol (4 Administrations)</title>
            <description>12 nmol given at 4 weekly intervals (4 administrations)</description>
          </group>
          <group group_id="O2">
            <title>HDM-SPIRE 20 Nmol</title>
            <description>20 nmol given at 4 weekly intervals (4 administrations)</description>
          </group>
          <group group_id="O3">
            <title>HDM-SPIRE 12 Nmol (8 Administrations)</title>
            <description>20 nmol given at 4 weekly intervals (8 administrations)</description>
          </group>
          <group group_id="O4">
            <title>HDM-SPIRE Placebo</title>
            <description>8 administrations at 4 weekly intervals</description>
          </group>
        </group_list>
        <measure>
          <title>Mean RMS in HDM-SPIRE Treatment Group Compared With Placebo</title>
          <description>Mean RMS (Rescue medication score) in HDM-SPIRE treatment groups compared with placebo groups.
The use of rhinoconjunctivitis rescue medications was recorded by the subject on a daily basis just before bedtime for approximately 21 days, 50-52 weeks after randomisation and was scored based on a previously published system as follows: 0 = no allergy rescue medication used per day; 0.5 = at least one dose of antihistamine eye drops used per day; 1 = at least one dose of oral antihistamine used per day; 2 = at least one dose of intranasal corticosteroid used per day; 3 = at least one dose of systemic corticosteroid used per day. The score was according to the highest level of rescue medication used and was not additive.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="165"/>
                <count group_id="O4" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" spread="0.048"/>
                    <measurement group_id="O2" value="0.51" spread="0.048"/>
                    <measurement group_id="O3" value="0.41" spread="0.047"/>
                    <measurement group_id="O4" value="0.55" spread="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days With no Rescue Medication Use in HDM-SPIRE Treatment Group Compared With Placebo</title>
        <description>The number of well days, i.e., days with no moderately or severely annoying symptoms and with no rescue medication used was calculated for all subjects over a period of approximately 21 days, 50-52 weeks after randomisation.</description>
        <time_frame>Weeks 50 to 52 after randomisation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HDM-SPIRE 12 Nmol (4 Administrations)</title>
            <description>12 nmol given at 4 weekly intervals (4 administrations)</description>
          </group>
          <group group_id="O2">
            <title>HDM-SPIRE 20 Nmol</title>
            <description>20 nmol given at 4 weekly intervals (4 administrations)</description>
          </group>
          <group group_id="O3">
            <title>HDM-SPIRE 12 Nmol (8 Administrations)</title>
            <description>20 nmol given at 4 weekly intervals (8 administrations)</description>
          </group>
          <group group_id="O4">
            <title>HDM-SPIRE Placebo</title>
            <description>8 administrations at 4 weekly intervals</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days With no Rescue Medication Use in HDM-SPIRE Treatment Group Compared With Placebo</title>
          <description>The number of well days, i.e., days with no moderately or severely annoying symptoms and with no rescue medication used was calculated for all subjects over a period of approximately 21 days, 50-52 weeks after randomisation.</description>
          <units>Days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="165"/>
                <count group_id="O4" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.9" spread="2.90"/>
                    <measurement group_id="O2" value="33.5" spread="2.89"/>
                    <measurement group_id="O3" value="33.9" spread="2.80"/>
                    <measurement group_id="O4" value="31.1" spread="2.812"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Upto 52 weeks after randomisation</time_frame>
      <group_list>
        <group group_id="E1">
          <title>HDM-SPIRE 12 Nmol (4 Administrations)</title>
          <description>12 nmol given at 4 weekly intervals (4 administrations)</description>
        </group>
        <group group_id="E2">
          <title>HDM-SPIRE 20 Nmol</title>
          <description>20 nmol given at 4 weekly intervals (4 administrations)</description>
        </group>
        <group group_id="E3">
          <title>HDM-SPIRE 12 Nmol (8 Administrations)</title>
          <description>20 nmol given at 4 weekly intervals (8 administrations)</description>
        </group>
        <group group_id="E4">
          <title>HDM-SPIRE Placebo</title>
          <description>8 administrations at 4 weekly intervals</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="178"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Urinary retention postoperative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Postoperative wound complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Post procedual haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Skin reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="140" subjects_at_risk="178"/>
                <counts group_id="E4" subjects_affected="124" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="59" subjects_affected="37" subjects_at_risk="180"/>
                <counts group_id="E2" events="54" subjects_affected="32" subjects_at_risk="178"/>
                <counts group_id="E3" events="54" subjects_affected="38" subjects_at_risk="178"/>
                <counts group_id="E4" events="58" subjects_affected="41" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="27" subjects_affected="22" subjects_at_risk="180"/>
                <counts group_id="E2" events="32" subjects_affected="24" subjects_at_risk="178"/>
                <counts group_id="E3" events="32" subjects_affected="21" subjects_at_risk="178"/>
                <counts group_id="E4" events="26" subjects_affected="20" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="180"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="178"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="178"/>
                <counts group_id="E4" events="16" subjects_affected="12" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="180"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="178"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="178"/>
                <counts group_id="E4" events="12" subjects_affected="11" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="180"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="178"/>
                <counts group_id="E3" events="14" subjects_affected="10" subjects_at_risk="178"/>
                <counts group_id="E4" events="9" subjects_affected="6" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="180"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="178"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="178"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="26" subjects_affected="10" subjects_at_risk="180"/>
                <counts group_id="E2" events="30" subjects_affected="11" subjects_at_risk="178"/>
                <counts group_id="E3" events="28" subjects_affected="13" subjects_at_risk="178"/>
                <counts group_id="E4" events="16" subjects_affected="12" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="180"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="178"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="178"/>
                <counts group_id="E4" events="11" subjects_affected="9" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="180"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="178"/>
                <counts group_id="E4" events="9" subjects_affected="6" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Wording included in the clinical protocol - The Investigator and Circassia will normally prepare a manuscript together. To avoid disclosures that may affect the proprietary rights of the Sponsor, the Investigator agrees to allow Circassia the opportunity to review all manuscripts and abstracts 60 days prior to submission for publication. Circassia reserves the right to include the report of this study in any regulatory documentation or submission or in any informational materials.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>VP Clinical Operations</name_or_title>
      <organization>Circassia Ltd</organization>
      <phone>+44 1865 405560</phone>
      <email>kirsten.evans@circassia.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

